Key statistics
On Tuesday, Cellectar Biosciences Inc (CLRB:NAQ) closed at 2.68, 9.39% above its 52-week low of 2.45, set on Dec 17, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.98 |
|---|---|
| High | 3.06 |
| Low | 2.66 |
| Bid | 2.61 |
| Offer | 2.85 |
| Previous close | 2.99 |
| Average volume | 29.73k |
|---|---|
| Shares outstanding | 4.24m |
| Free float | 4.07m |
| P/E (TTM) | -- |
| Market cap | 12.68m USD |
| EPS (TTM) | -10.78 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
- Cellectar Biosciences Expands Global Intellectual Property Estate
- Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
- Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
- Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
- Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
- Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
- Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
More ▼
